A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
Relapsed or Refractory Acute Myeloid Leukemia|Relapsed or Refractory Chronic Myelomonocytic Leukemia|Relapsed or Refractory Myelodysplastic Syndrome
DRUG: NC525
To evaluate the frequency, duration, and severity of treatment-emergent adverse events [Safety and Tolerability]., Toxicity grading per NCI CTCAE v5.0., Up to 24 months|To evaluate dose-limiting toxicities (DLTs) of NC525., Toxicity grading per NCI CTCAE v5.0., Up to 56 days|Define a recommended Phase 2 dose (RP2D) of NC525, A Bayesian Optimal Interval (BOIN) design will be utilized to determine a recommended Phase 2 dose (RP2D) for NC525., Up to 24 months|Define a minimally active dose (MAD) of NC525, A BOIN design will be utilized to determine a MAD, Up to 24 months|Define a pharmacologically active dose (PAD) of NC525, A BOIN design will be utilized to determine a PAD, Up to 24 months|Define a maximum tolerated dose (MTD) of NC525, A BOIN design will be utilized to determine a MTD, Up to 24 months
To evaluate the clinical benefit of NC525 by assessing Objective Response (OR)., Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures., Until disease progression, up to 24 months|To evaluate the clinical benefit of NC525 by assessing Event-free survival (EFS)., Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures., Until disease progression, up to 24 months|To evaluate the clinical benefit of NC525 by assessing Overall survival (OS)., Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures., Until disease progression, up to 24 months|Assessment of time to achieve response, defined as CR, CRi, or CRh, Disease Assessments will be performed using the European Leukemia Net (ELN) Guidelines for the ELN Outcome Measures., Cycle 1 Day 1 to day remission is achieved, up to 24 months (each cycle is 28 days)|Maximum Observed Serum Concentration (Cmax) of NC525, During Cycles 1, 2, 3, 5, 7, and 11 (each cycle is 28 days)|Terminal Half-life (t1/2) of NC525, During Cycles 1, 2, 3, 5, 7, and 11 (each cycle is 28 days)|Area under the serum concentration versus time curve (AUC) of NC525, During Cycles 1, 2, 3, 5, 7, and 11 (each cycle is 28 days)
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.